-

MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company

Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.

Rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector.

ISS, one of the world’s leading ratings agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.

MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders. 

The first product based on MedinCell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipe of other products follows.

Access here the complete press release

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL):

“This recognition is a tribute to MedinCell efforts and performance.” said Christophe Douat, CEO of MedinCell. “Strong ESG performance is an increasingly important factor in attracting investors and the Prime status received from ISS ESG is a valuable guide for those seeking to identify companies that are driving positive change. We have always considered that our sustainable company model is inseparable from our raison d’être.”

MedinCell began to formalize its corporate and social responsibility with the inclusion of its raison d’être in its statutes in 2019: Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. In 2022, the Company established an ESG committee at its board. Other achievements include the embedment of ESG culture and the implementation of quantitative ESG objectives.

Contacts

MedinCell
David Heuzé
Head of Communications
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Head of Communications
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

More News From MedinCell

Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: UZEDY® U.S. net sales reached $85M in Q3 2026, up 96% year-on-year, according to third-quarter results reported today by Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals (NYSE and TASE: TEVA). Teva raised its 2026 UZEDY® revenue outlook to $290-$310M, from $270-$290M previously. UZEDY® generated $225M in U.S. net sales over the first nine months of 2026, exceeding the $191M reported for full-year 2025. UZEDY® commercial performance in...

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple ther...

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments acr...
Back to Newsroom